Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Second Genome

Second Genome
2009 FOUNDED
PRIVATE STATUS
51-60 EMPLOYEES
Grant LATEST DEAL TYPE
14 INVESTORS
Description

Provider of microbial profiling services designed to to improve health & wellness. The company's microbiome data platform utilizes microbiome biology, bioninformatics, computation and machine learning to identify prospective therapeutic lead candidates, bacteria, peptides and metabolites which benefit human health, enabling therapeutic candidates to be advanced through pharmaceutical clinical programs. The company's platform is also utilized in agriculture as a resource for mining the agricultural microbiome.

Formerly Known As
Phylotech
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
  • 341 Allerton Avenue
  • South San Francisco, CA 94080
  • United States

+1 (650) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Second Genome’s full profile, request a free trial.

Second Genome Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Grant 03-Oct-2017 000.00 Completed Clinical Trials - Phase 1
4. Later Stage VC (Series B) 13-Jul-2016 000.00 000.00 0000 Completed Clinical Trials - Phase 1
3. Early Stage VC (Series A) 07-Jun-2013 000.00 000.00 000.00 Completed Startup
2. Early Stage VC (Series A) 09-Aug-2011 $5M $6.24M 000.00 Completed Startup
1. Seed Round 07-Jul-2010 $1.24M $1.24M 00.00 Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

Second Genome Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series B 000,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
Series A 00,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
Seed 5,607,290 $0.000100 $0.02 $0.22 $0.22 1x $0.22 2.12%
To view this company’s complete Cap Table, request access »

Second Genome Competitors (25)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Whole Biome Venture Capital-Backed San Francisco, CA 00 000.00 00000000000 000.00
00000000 Corporate Backed or Acquired Cambridge, MA 0 00000000000
00000 000000000000 Formerly VC-backed Cambridge, MA 000 00000 000000000 00000
0000000 0000000000 Venture Capital-Backed Cambridge, MA 00 000.00 00000000000 000.00
00000 Venture Capital-Backed Ness Ziona, Israel 00 0000 00000000000 0000
To view this company’s complete list of competitors, request access »

Second Genome Investors (14)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Digitalis Ventures Venture Capital Minority 000 0000 000000 0
Lifeforce Capital Venture Capital Minority 000 0000 000000 0
Lifeforce Ventures Venture Capital Minority 000 0000 000000 0
Lightstone Ventures Venture Capital Minority 000 0000 000000 0
Matthew Winkler Angel (individual) Minority 000 0000 000000 0
You’re viewing 5 of 14 investors. Get the full list »

Second Genome Executive Team (13)

Name Title Board
Seat
Contact
Info
Todd DeSantis Co-Founder and Vice-President of Informatics
Glenn Nedwin Ph.D Chief Executive Officer
Karim Dabbagh Ph.D Chief Scientific Officer
Brian Dowd Senior Vice President, Finance & Controller
Gary Andersen Ph.D Co-Founder & Advisor

6 Former Executives

You’re viewing 5 of 13 executives. Get the full list »

Second Genome Board Members (11)

Name Representing Role Since Contact
Info
Bradley Margus Self Board Member 000 0000
Carole Nuechterlein JD Roche Venture Fund Board Member 000 0000
Corey Goodman Ph.D Self Chairman & Co-Founder 000 0000
Elaine Jones Ph.D Pfizer Ventures Board Member 000 0000
Geoffrey Smith JD Digitalis Ventures Board Observer 000 0000

3 Former Board Members

You’re viewing 5 of 11 board members. Get the full list »